TRIMTECH Therapeutics has appointed Alison Lawton as the new Chair of its Board of Directors.
Lawton’s expertise spans operations, drug development and strategic leadership. She was most recently CEO of Kaleido Biosciences, preceding which she served as President and COO. She has held senior leadership positions at Genzyme (a Sanofi company), where she oversaw global regulatory affairs, as well as Aura Biosciences and X4 Pharmaceuticals.
Over Lawton’s 35 years of pharmaceutical and biotechnology experience, she has led global regulatory strategy for a wide variety of product approvals, as well as gaining significant boardroom experience.
She is currently Chair of the Board of Directors at Dianthus Therapeutics and a Board Member at ProQR Therapeutics and BlueRock Therapeutics, and previously served on the boards of companies such as Spyre Therapeutics and X4 Pharmaceuticals.
“TRIMTECH has built a strong scientific and organisational foundation to deliver on its mission,” Lawton commented.
TRIMTECH is a biotechnology company focused on the development of novel small molecule therapies which target protein aggregates associated with neurodegenerative diseases. Lawton will assist in accelerating the advancement of TRIMTECH’s portfolio and guide the company’s next stage of growth.
Nicola Thompson, CEO of TRIMTECH, said of Lawton: “Alison’s experience leading organisations through complex growth phases complements our science-led approach and will strengthen the Board as they guide TRIMTECH towards our goal of delivering accessible, disease-modifying therapies for neurodegeneration.”